51 related articles for article (PubMed ID: 1796296)
1. Tumor necrosis factor stimulates urokinase-type plasminogen activator and inhibitor type 1 production in A549 lung carcinoma cells: treatment of monolayer and tridimensional cultures.
Dosne AM; Beaupain R; Samama M
Semin Thromb Hemost; 1991 Jul; 17(3):240-5. PubMed ID: 1796296
[No Abstract] [Full Text] [Related]
2. Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
Heidtmann HH; Hofmann M; Jacob E; Erbil C; Havemann K; Schwartz-Albiez R
Cancer Res; 1989 Dec; 49(24 Pt 1):6960-5. PubMed ID: 2555056
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor induction of urokinase-type plasminogen activator in human endothelial cells.
Niedbala MJ; Stein M
Biomed Biochim Acta; 1991; 50(4-6):427-36. PubMed ID: 1801706
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells.
Allan EH; Zeheb R; Gelehrter TD; Heaton JH; Fukumoto S; Yee JA; Martin TJ
J Cell Physiol; 1991 Oct; 149(1):34-43. PubMed ID: 1834680
[TBL] [Abstract][Full Text] [Related]
5. Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells.
Niiya M; Niiya K; Kiguchi T; Shibakura M; Asaumi N; Shinagawa K; Ishimaru F; Kiura K; Ikeda K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2003 Nov; 52(5):391-8. PubMed ID: 12908082
[TBL] [Abstract][Full Text] [Related]
6. The THP-1 cell line is a urokinase-secreting mononuclear phagocyte with a novel defect in the production of plasminogen activator inhibitor-2.
Gross TJ; Sitrin RG
J Immunol; 1990 Mar; 144(5):1873-9. PubMed ID: 2307845
[TBL] [Abstract][Full Text] [Related]
7. Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1.
Bruckner A; Filderman AE; Kirchheimer JC; Binder BR; Remold HG
Cancer Res; 1992 Jun; 52(11):3043-7. PubMed ID: 1375533
[TBL] [Abstract][Full Text] [Related]
8. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor and pro-inflammatory cytokines regulate the expression of components of plasminogen activation system in U373-MG astrocytoma cells.
Kasza A; Kowanetz M; Poślednik K; Witek B; Kordula T; Koj A
Cytokine; 2001 Dec; 16(5):187-90. PubMed ID: 11814314
[TBL] [Abstract][Full Text] [Related]
10. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
Allan EH; Martin TJ
J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
[TBL] [Abstract][Full Text] [Related]
11. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells.
Rosanò L; Varmi M; Salani D; Di Castro V; Spinella F; Natali PG; Bagnato A
Cancer Res; 2001 Nov; 61(22):8340-6. PubMed ID: 11719468
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator regulation in osteoblasts: parathyroid hormone inhibition of type-1 plasminogen activator inhibitor and its mRNA.
Fukumoto S; Allan EH; Yee JA; Gelehrter TD; Martin TJ
J Cell Physiol; 1992 Aug; 152(2):346-55. PubMed ID: 1322417
[TBL] [Abstract][Full Text] [Related]
13. Changes in the fibrinolytic components of cultured human umbilical vein endothelial cells induced by endotoxin, tumor necrosis factor-alpha and interleukin-1alpha.
Orbe J; Chordá C; Montes R; Páramo JA
Haematologica; 1999 Apr; 84(4):306-11. PubMed ID: 10190943
[TBL] [Abstract][Full Text] [Related]
14. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
15. Correlation between urokinase-type plasminogen activator production and the metastatic ability of human rectal cancer cells.
Marutsuka K; Suzumiya J; Kataoka H; Komada N; Koono M; Sumiyoshi A
Invasion Metastasis; 1991; 11(4):181-91. PubMed ID: 1765431
[TBL] [Abstract][Full Text] [Related]
16. Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype.
Swiercz R; Wolfe JD; Zaher A; Jankun J
Clin Cancer Res; 1998 Apr; 4(4):869-77. PubMed ID: 9563880
[TBL] [Abstract][Full Text] [Related]
17. Retinoids increase urokinase-type plasminogen activator production by human retinal pigment epithelial cells in culture.
Immonen I; Sirén V; Stephens RW; Liesto K; Vaheri A
Invest Ophthalmol Vis Sci; 1993 May; 34(6):2062-7. PubMed ID: 8491555
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of cell-surface-associated plasminogen activation in cultured keratinocytes by interleukin-1 beta and tumor necrosis factor-alpha.
Bechtel MJ; Reinartz J; Rox JM; Inndorf S; Schaefer BM; Kramer MD
Exp Cell Res; 1996 Mar; 223(2):395-404. PubMed ID: 8601416
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the plasminogen activator system in non-small cell lung cancer cell lines by growth factors EGF, TGF-alpha and TGF-beta.
Heidtmann HH; Havemann K; Schwartz-Albiez R
Br J Cancer; 1992 Feb; 65(2):154-6. PubMed ID: 1310869
[No Abstract] [Full Text] [Related]
20. [Plasminogen activator inhibitors from neoplastic tissues].
Mirowski M; Wierzbicki R
Postepy Hig Med Dosw; 1991; 45(1-2):119-27. PubMed ID: 1923993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
